The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Preliminary ProgramFull Access

SATURDAY MAY 1

Published Online:https://doi.org/10.1176/pn.39.4.0005

8 a.m.-Noon

CME Courses 1-3

9 a.m.-4 p.m.

CME Courses 4-6

10 a.m.-5 p.m.

Registration/Course Enrollment Open

APA Exhibits Open

Publishers’ Bookfair Open

12:30 p.m.-3:30 p.m.

Industry-Supported Symposia

IS1. Treatment Resistance: Concepts and Management in Mood and Anxiety DisordersSupported by Janssen Pharmaceutica and Research Foundation

  A. Treatment Resistance in Mood and Anxiety Disorders: Evidence From Clinical Trials Ellen Frank, Ph.D.

  B. Psychotherapeutic Approaches for Patients With Treatment-Resistant Mood and Anxiety Disorders Edna B. Foa, Ph.D.

  C. Clinical Pathways for Mood and Anxiety Disorders Waguih W. Ishak, M.D.

  D. Emerging Treatment Options in Treatment-Resistant Mood and Anxiety Disorders Mark H. Rapaport, M.D.

IS2. Preventive Psychiatry in Mood Disorders: A New Frontier Supported by GlaxoSmithKline

  A. Identification of Risk Factors for Development of Depression: Focus on Early-Life Trauma Charles B. Nemeroff, M.D.

  B. Achieving the Optimal Balance Between Treatment of Maternal Depression and Infant Medication Exposure Zachary N. Stowe, M.D.

  C. Functional Brain Imaging: Subtyping Depression Helen S. Mayberg, M.D.

  D. Genetic Research in Psychiatry: Diagnostic and Therapeutic Implications Stephan Claes, M.D.

IS3. Bipolar Disorder and Alcoholism: Diagnostic Challenges and Therapeutic Interventions Supported by Ortho-McNeil Pharmaceuticals

  A. Neurobiology of Alcohol Withdrawal Hugh Myrick, M.D.

  B. Pharmacotherapy for Alcoholism Bankole A. Johnson, M.D.

  C. The Impact of Alcoholism on the Presentation and Course of Bipolar Disorder Susan L. McElroy, M.D.

  D. The Role of Mood Stabilizers in Bipolar Disorder With Comorbid Alcohol Dependence Joseph F. Goldberg, M.D.

  E. Bipolar Illness, Substance Abuse Comorbidity, and the Legal System Cameron D. Quandeck, Ph.D.

IS4. Adult ADHD: Clinical Utility and Validity Supported by Eli Lilly and Company

  A. Prevalence of Adult ADHD in the United States: Results From the National Comorbidity Survey Replication (NCS-R) Ronald C. Kessler, Ph.D.

  B. Development and Validation in the National Comorbidity Survey (NSC-R) Cohort Lenard A. Adler, M.D.

  C. Current Concepts in the Neurobiology of ADHD Joseph Biederman, M.D.

  D. Treatment Options and Response Patterns in Adult ADHD Margaret D. Weiss, M.D.

  E. Our New Understanding of the Prevalence, Impairments, Comorbidity, and Treatment of Adults With ADHD Thomas J. Spencer, M.D.

IS5. Toward DSM-V: Phenomenology, Neurobiology, and Treatment Response in Depression Supported by Cephalon Inc.

  A. Pathophysiology of Major Depression: Monoamines, Peptides, and Neurotrophins Kerry J. Ressler, M.D.

  B. Homology Between Pathophysiology and Symptoms in Major Depression Boadie W. Dunlop, M.D.

  C. Enhancing Emergence of Antidepressant Benefit Charles DeBattista, M.D.

  D. Pharmacological Approaches to Management of Residual Symptoms in Depression Maurizio Fava, M.D.

  E. MIND: Lessons From the Brain Philip T. Ninan, M.D.

1 p.m.-5 p.m.

CME Courses 7-12

6 p.m.-9 p.m.

Industry-Supported Symposia

IS6. The Role of Dopamine in Health and Illness: Science to Practice Supported by AstraZeneca Pharmaceuticals

  A. The Role of Dopamine as a Mediator of Normal Human Reward Nora D. Volkow, M.D.

  B. From Dopamine to Salience to Psychosis: Why Antipsychotics Are Antipsychotic Shitij Kapur, M.D.

  C. Dopamine and Neuroleptic Dysphoria in Practice Peter J. Weiden, M.D.

  D. The Role of Dopamine in Cognition Rajiv Tandon, M.D.

  E. The Role of Dopamine in the Neurobiology of Sexual Dysfunction Abdelouahed Elmouchtari, M.D.

IS7. Impulsivity: Emerging Clinical Perspectives Supported by Ortho-McNeil Pharmaceuticals

  A. Neurobiology of Impulsive Behavior Alan C. Swann, M.D.

  B. When Does Impulsive Behavior Become Pathologic? Ernest S. Barratt, M.D.

  C. Clinical Issues of Impulsivity in Psychiatry Dan J. Stein, M.D.

  D. Addressing Impulsive Behavior in Eating Disorders Renu Kotwal, M.D.

  E. Identifying the Spectrum of Impulse-Control Disorders Eric Hollander, M.D.

IS8. Bipolar Disorder: Improving Outcomes When Theory, Science, and Clinical Practice Converge Supported by Eli Lilly and Company

  A. The Convergence of Pharmacotherapy and Psychotherapy in Maintenance Treatment of Bipolar Disorder Paul E. Keck Jr., M.D.

  B. Considerations in the Female Patient During Childbearing Years Adele C. Viguera, M.D.

  C. Choosing Treatments in Bipolar Depression: What, When, and Why? Roy H. Perlis, M.D.

  D. Cognitive Functioning Outcomes: From First Episode to Functional Recovery Deborah A.Yurgelun-Todd, Ph.D.

  E. Translating Research Into Clinical Practice: From the Bench to the Trenches Joseph F. Goldberg, M.D.

IS9. GAD: Evidence-Based Considerations From Pathophysiology to Long-Term Management Supported by Pfizer Inc.

  A. Prevalence of GAD in the U.S.: Results from the National Comorbidity Survey Replication Ronald C. Kessler, Ph.D.

  B. Distinguishing GAD: Unique Characteristics Wei Zhang, M.D.

  C. The Molecular and Cellular Pathophysiology of GAD Carl Salzman, M.D.

  D. Cognitive-Behavior Therapy for the Treatment of GAD Michelle G. Newman, Ph.D.

  E. Pharmacotherapies for GAD: From Rough Empiricism to Elegant Evidence John H. Greist, M.D.

IS10. Sex, Sexuality, and 5HT Supported by GlaxoSmithKline

  A. Do Sexual Side Effects of Most Antidepressants Jeopardize Romantic Love and Marriage? Helen E. Fisher, Ph.D.

  B. Love and Sex Ethel S. Person, M.D.

  C. Talking to Gay Patients About Sex: What Do You Need to Know? Serena Y. Volpp, M.D.

  D. Effects of Psychiatric Illness and Medication on Sexual Function Anita L.H. Clayton, M.D.

  E. Talking About Sexual Dysfunction to Enhance Adherence With Medication Philip R. Muskin, M.D.

IS11. Interface Between Depression and Medical Illness Supported by Wyeth Pharmaceuticals

  A. Heartache and Heartbreak: Depression and Cardiovascular Disease Charles B. Nemeroff, M.D.

  B. The Relationship of Depression to Cancer and HIV Infection David Spiegel, M.D.

  C. Comorbidity of Depression in Neurological Disorders William M. McDonald, M.D.

  D. Mood Disorders and Medical Illness: Diabetes, Osteoporosis, Obesity, and Pain Robert N. Golden, M.D.

  E. Mood Disorders in the Medically Ill: The Patient’s Perspective Lydia J. Lewis, B.A.